Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk
Pratik Choudhary, John Shin, Yongyin Wang, Mark L Evans, Peter J Hammond, David Kerr, James A M Shaw, John C Pickup, Stephanie A Amiel, Pratik Choudhary, John Shin, Yongyin Wang, Mark L Evans, Peter J Hammond, David Kerr, James A M Shaw, John C Pickup, Stephanie A Amiel
Abstract
Objective: To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia.
Research design and methods: The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes.
Results: There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart.
Conclusions: Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.
Trial registration: ClinicalTrials.gov NCT01267175.
Figures
References
- Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476
- Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The RealTrend study. Diabetes Care 2009;32:2245–2250
- O’Connell MA, Donath S, O’Neal DN, et al. . Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52:1250–1257
- Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care 2010;35:1004–1008
- Buckingham B, Block J, Burdick J, et al. ; Diabetes Research in Children Network. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005;7:440–447
- UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140–1147
- Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774
- Guerci B, Meyer L, Sallé A, et al. . Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999;84:2673–2678
- Pickup JC, Viberti GC, Bilous RW, et al. . Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia 1982;22:175–179
- Jones TW, Porter P, Sherwin RS, et al. . Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998;338:1657–1662
- Monsod TP, Flanagan DE, Rife F, et al. . Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002;25:889–893
- Keenan DB, Cartaya R, Mastrototaro JJ. Accuracy of a new real-time continuous glucose monitoring algorithm. J Diabetes Sci Technol 2010;4:111–118
Source: PubMed